NEW PRODUCTS – AUSTRALIA

Seven West’s video-on-demand puzzle

roymorgansocial Leave a comment

Original article by Jake Mitchell
The Australian Financial Review – Page: 31 : 28-Jul-14

Nine Entertainment Company plans to launch a subscription video-on-demand service, potentially before the end of 2014. At one stage it appeared that Nine and arch-rival Seven West Media could have jointly developed the StreamCo product, and this may still be a possibility. StreamCo’s main competitor is likely to be US-based Netflix, which is expected to debut in Australia in 2015. Nine has also bought redeemable preference shares in Quickflix

CORPORATES
NINE ENTERTAINMENT COMPANY HOLDINGS LIMITED – ASX NEC, SEVEN WEST MEDIA LIMITED – ASX SWM, NETFLIX INCORPORATED, QUICKFLIX LIMITED – ASX QFX, FOXTEL MANAGEMENT PTY LTD, HOYTS GROUP PTY LTD, HBO, HULU LLC, TEN NETWORK HOLDINGS LIMITED – ASX TEN

Bendigo ‘redy’ to pay through smartwatches

roymorgansocial Leave a comment

Original article by Shaun Drummond, Ruth Liew
The Australian Financial Review – Page: 17 : 28-Jul-14

Bendigo & Adelaide Bank has launched a new mobile payments network that is dubbed "redy" and can be used with a Samsung smartwatch and smartphone. The technology was developed by the regional bank’s Community Telco subsidiary. The redy system uses QR codes to verify transactions, while customers also receive an online token for each redy transaction, which can be converted into cash that can be spent or donated to charity

CORPORATES
BENDIGO AND ADELAIDE BANK LIMITED – ASX BEN, COMMUNITY TELCO AUSTRALIA PTY LTD, PAYPAL AUSTRALIA PTY LTD, SAMSUNG CORPORATION, COLES GROUP LIMITED, WESFARMERS LIMITED – ASX WES, GOOGLE INCORPORATED

Mesoblast sows the seeds for stem cell success

roymorgansocial Leave a comment

Original article by Rick Wallace
The Australian – Page: 15 & 16 : 28-Jul-14

A new regulatory environment in Japan means it will be the initial market in which Australian-listed biotechnology group Mesoblast launches its revolutionary stem cells therapy product. CEO Silviu Itescu notes that this will be a world first, and should boost stock analysts’ forecasts for the company. A 2016 launch in the US is also being aimed for. In that nation Mesoblast has concluded phase III clinical trials of mesenchymal stem cells for treating childhood graft-versus-host-disease. The group has cash holdings of about $A220m, and can allocate funding to separate trials of its degenerative disc repair product

CORPORATES
MESOBLAST LIMITED – ASX MSB, UNITED STATES. FOOD AND DRUG ADMINISTRATION, JCR PHARMACEUTICALS COMPANY LIMITED, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, GOLDMAN SACHS AUSTRALIA PTY LTD, BELL POTTER SECURITIES LIMITED, BELL FINANCIAL GROUP LIMITED – ASX BFG